TIDMAMP

RNS Number : 3333V

Amphion Innovations PLC

02 November 2017

Amphion Innovations plc

("Amphion" or "the Company")

Order Dismissing DataTern Case

London and New York, 2 November 2017 - Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, announces that on 20 October 2017 the case brought by DataTern Inc. ("DataTern"), a wholly-owned subsidiary of Amphion, against MicroStrategy Inc. and certain of its customers was dismissed.

The reason for the case dismissal was the withdrawal of DataTern's legal counsel and the inability of DataTern to identify and appoint a successor counsel in the short time frame set by the Court.

It remains DataTern's considered opinion that the 502 and 402 patents are both valid and being infringed by a wide range of companies that are practicing this critical art. In order to pursue these claims though, DataTern needs to be able to fund the expenses in the programme and efforts to find a suitable funding source and successor legal counsel are continuing.

For further information please contact:

 
 Amphion Innovations                                 Tel: +1 (212) 210 
                                                                  6224 
 Charlie Morgan 
 
 Panmure Gordon Limited (Nominated Adviser         Tel: +44 (0)20 7886 
  and Corporate Broker)                                           2500 
 Freddy Crossley / Duncan Monteith (Corporate 
  Finance) 
 Charlie Leigh-Pemberton (Corporate Broking) 
 
 Northland Capital Partners Limited (Joint         Tel: +44 (0)20 3861 
  Corporate Broker)                                               6625 
 Patrick Claridge / David Hignell (Corporate 
  Finance) 
 John Howes (Corporate Broking) 
 
 Walbrook PR                                       Tel: +44 (0)20 7933 
                                                               8780 or 
 Mike Wort/ Paul McManus                        amphion@walbrookpr.com 
 
 

About Amphion Innovations plc

Amphion Innovations is a developer of medical, life science and technology businesses. We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in a small number of Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies.

On the web: www.amphionplc.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCEAAFFEASXFAF

(END) Dow Jones Newswires

November 02, 2017 03:00 ET (07:00 GMT)

Amphion Innovations (LSE:AMP)
Historical Stock Chart
From Aug 2024 to Sep 2024 Click Here for more Amphion Innovations Charts.
Amphion Innovations (LSE:AMP)
Historical Stock Chart
From Sep 2023 to Sep 2024 Click Here for more Amphion Innovations Charts.